6. Yucai Wang, Shouhao Zhou, Fang Yang, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis[J]. JAMA Oncol. 2019 Jul 1;5(7):1008-1019.
[7] Yucai Wang, Shouhao Zhou, Fang Yang, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis[J]. JAMA Oncol. 2019 Jul 1;5(7):1008-...
In this review, we systematically summarized the pathogenesis, especially the molecular mechanisms of PD, the classical research models, clinical diagnostic criteria, and the reported drug therapy strategies, as well as the newly reported drug candidates in clinical trials. We also shed light on the...
6. Yucai Wang, Shouhao Zhou, Fang Yang, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis[J]. JAMA Oncol. 2019 Jul 1;5(7):1008-1019.
中国帕金森病注册登记研究(The Chinese Parkinson's Disease Registry, CPDR)是一项由中南大学湘雅医院发起的、多中心的、全国性的PD队列研究(在Clinical Trials网站登记注册(NCT03887663))。CPDR将通过互联网为授权人员提供一个用户友好的、加密的注册平台。CPDR的登记内容包括:人口统计学特征、临床特征、环境因素、家族史...
综合默沙东产品管线和ClinicalTrials来看，默沙东尚未将两款PD-1激动剂推进至临床阶段。在默沙东之后，吉利德在2022年8月以约4.05亿美元收购了MiroBio，根据bioSeedin当时的报道PD-1宝刀未老，BTLA另辟蹊径，吉利德4亿美元收购自免管线显示，吉利德本次收购的核心资产之一便是PD-1激动剂MB151，收购时已经处于IND阶段...
This information can help researchers better understand the active and approved clinical trials in China, as well as the ongoing research regarding PD-1 and PD-L1 inhibitors. 展开 关键词: PD-1 inhibitor PD-L1 inhibitor Clinical trials China ...
We summarize the ongoing international and domestic clinical trials using PD-1 and PD-L1 inhibitors to treat lung cancer. This information can help researchers better understand the active and approved clinical trials in China, as well as the ongoing research regarding PD-1 and PD-L1 inhibitors....
(PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunotherapy in 270 clinical studies. However, Chinese clinical trials of these agents remain in the early stages. We summarize the ongoing international and domestic clinical trials using PD-1 and PD-L1 ...
近日(11月11日),nature reviews drug discovery杂志上发布了一篇题为“Combinations take centre stage in PD1/PDL1 inhibitor clinical trials”的报告,总结了抗PD-1/L1 mAb(单克隆抗体)临床试验的现状以及患者招募中的挑战。 在临床开发中的现有免疫肿瘤(IO)试剂中,抗PD-1和抗PD-L1 单抗取得了最大的成功。